Preparation of Baicalin Liposomes Using Microfluidic Technology and Evaluation of Their Antitumor Activity by a Zebrafish Model.

Baicalin (BCL), a well-known flavonoid molecule, has numerous therapeutic applications. However, its low water solubility and bioavailability limit its applicability. Microfluidics is a new method for liposome preparation that provides efficient and rapid control of the process, improving the stability and controllability. This study used microfluidic techniques to create baicalin liposomes (BCL-LPs), first screening for optimal total flow rates (TFR) and flow rate ratios (FRR), and then optimizing the phospholipid concentration, phospholipid-to-cholesterol ratio, and Tween-80 concentration using univariate and response surface methodology approaches. The study found that the ideal phospholipid content was 9.5%, the phospholipid-to-cholesterol ratio was 9:1 (:), and the Tween-80 concentration was 15%. BCL-LPs achieved 95.323% ± 0.481% encapsulation efficiency under the optimum circumstances. Characterization indicated that the BCL-LPs were spherical and uniform in size, with a mean diameter of 62.32 nm ± 0.42, a polydispersity index of 0.092 ± 0.009, and a zeta potential of -25.000 mV ± 0.216. experiments found that BCL-LPs had a better slow-release effect and stability than the BCL monomer. In zebrafish bioassays, BCL-LPs performed better than BCL monomer in terms of biological activity and bioavailability. The established method provided a feasible medicine delivery platform for BCL and could apply for the transport and encapsulation of more natural compounds, expanding the applications of drug delivery systems in healthcare and cancer therapies.